AJMC Staff

US reports a record number of new coronavirus disease 2019 (COVID-19) cases; FDA reviewers endorse an Alzheimer disease drug; CDC director calls for asymptomatic testing strategy.

A decision was upheld that Johnson & Johnson (J&J) must pay a $2.1-billion fine from a 2018 court decision; 3 major drug distributors face up to $18 billion in opioid-related fines; a new diabetes prevention platform may assist in symptom prevention.

Patients with mild cases of coronavirus disease 2019 (COVID-19) had cellular immunity after 6 months; political support among caregivers of patients with COVID-19 was spotlighted; 2 lots of type 2 diabetes (T2D) drug metformin recalled over possible contamination.

Nearly half of hospitals to get lower Medicare payments due to patients' readmission history; open enrollment begins for health coverage under the Affordable Care Act; study models projected cases and deaths from COVID-19 to the president's rallies.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Migraine can affect children’s quality of life, and a recent study examined the use of melatonin to treat pediatric acute migraine.

The procedure might work best in patients who have had multiple sclerosis (MS) for less than 10 years, the report said.

The study compared patients given-low-dose ketamine with those given morphine for acute pain relief.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The United States sees a daily record in new coronavirus disease 2019 (COVID-19) cases; grocery workers are at a greater risk of COVID-19 infection; the risks of gene editing.

The FDA has approved new indications for Foundation Medicine's liquid biopsy assay and also its tissue-based companion diagnostic for solid tumors.

Ransomware attacks threaten US hospitals; the Trump administration purchases 300,000 doses of an antibody drug; CMS releases coverage plan for COVID-19 vaccine and treatments.

Hospitals struggle to respond adequately to the pandemic surge; enrollment is almost complete for Pfizer and BioNTech’s coronavirus disease 2019 (COVID-19) vaccine candidate trial; the CDC reports mixed results for COVID-19 mitigation behaviors.

AstraZeneca and Johnson & Johnson will restart trials of their vaccine candidates against coronavirus disease 2019 (COVID-19); the United States hits a record high 2-day total of COVID-19 infections; strategies can help ease stress amid the coming election.

Understanding patients’ social determinants of health (SDOH), including their past experiences with discrimination and medical mistrust, can help improve patient-reported outcomes (PROs), according to new research.

During Kidney Week, various studies discussed not only the effect coronavirus disease 2019 (COVID-19) has on patients with end-stage renal disease (ESRD) but also new attacks of acute kidney injury (AKI) that can cause severe illness or even death.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Two abstracts presented at a recent multiple sclerosis meeting examined depression in pregnancy and pregnancy outcomes in ozanimod trials.

The FDA has approved Gilead’s remdesivir; presidential nominees debate health care reforms; US endorses international antiabortion declaration.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Purdue Pharma will pay $8.3 billion in criminal charges; the CDC expands its definition of "close contact"; Ireland announces new lockdown.

The director of the National Institutes of Health speaks out on his prediction for vaccine approval; Americans are having difficulty finding and trusting coronavirus disease 2019 (COVID-19) information; pandemic-related trends in Alaska are on the rise.

The proposed deadline for a second coronavirus disease 2019 (COVID-19) stimulus package has arrived; there is a new 3-digit number for mental health emergencies; several treatment options are available for patients who have COVID-19.

Pfizer will not apply for emergency use authorization of its coronavirus disease 2019 (COVID-19) vaccine until at least mid-November; infectious disease experts warn of a potential third wave of COVID-19; rates of major depression increased among millennials.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

A recent analysis illustrated how a combination of different genomic approaches discovered actionable alterations in 44% of patients with metastatic breast cancer.

The safety profile of nivolumab plus chemotherapy was also consistent with previously reported studies in NSCLC, the researchers said.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The FDA strengthens its guidance for pain reliever use in pregnant women; the United States sees its greatest increase in coronavirus disease 2019 (COVID-19) cases since August; studies point to association of blood type and COVID-19 risk.

Wildfire smoke contributes to an uptick in emergency department visits; President Donald Trump holds a rally in Iowa; FDA approves first ebola treatment.